Results 111 to 120 of about 7,475 (211)

All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults. [PDF]

Diabetes Care, 2023
Wei Y, Herzog K, Ahlqvist E, Andersson T, Nyström T, Zhan Y, Tuomi T, Carlsson S.   +7 more
europepmc   +1 more source

Combination Versus Monotherapy in Acute Anti‐LGI1 Encephalitis: A Real‐World Dose Optimization Analysis

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Combined IVIg and 500 mg/day IVMP achieve superior efficacy over monotherapies in anti‐LGI1 encephalitis, with optimal safety. Higher‐dose IVMP (1000 mg) accelerates response but increases adverse events, particularly in diabetic patients. Cognitive deficits persist post‐treatment, necessitating long‐term management.
Yao Tan, Ming Sun, Qinqin Liu, Beibei Huang, Chao Wu, Jie Lu, Donglin Zhu   +6 more
wiley   +1 more source

Joint modeling of longitudinal and time‐to‐event data for dynamic disease risk prediction using proteomics

Protein Science, Volume 35, Issue 6, June 2026.
Abstract Biomedical studies increasingly incorporate longitudinal data, enabling us to track individual disease processes over time at the molecular level, and to discover associations of the molecular profiles with the outcome of interest, such as the onset of a disease.
Markus Lindén, Tea Ammunét, Tommi Välikangas, Laura L. Elo, Tomi Suomi   +4 more
wiley   +1 more source

Association between sleep duration and cognitive function and emotional disorders in middle‐aged and elderly patients with cerebral small vessel disease

Sleep Research, Volume 3, Issue 2, Page 121-134, June 2026.
Abstract Objectives To investigate the association between the sleep duration with cognitive impairment in middle‐aged and elderly patients with cerebral small vessel disease (CSVD). Methods This cross‐sectional study enrolled hospitalized patients aged ≥55 years diagnosed with CSVD between November 2021 and August 2023.
Chunmei Long, Yunying Wu, Sha Wang, Ziwei Gong, Ye Wang   +4 more
wiley   +1 more source

Glycemic Variability Bridges Time in Range and Time in Tight Range: A Unified Equation for Both Type 1 and Type 2 Diabetes Based on Large‐Scale Continuous Glucose Monitoring Data

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5068-5077, June 2026.
ABSTRACT Aims This study aimed to establish a regression model for the relationship between time in range (TIR) and time in tight range (TITR) in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) based on real‐world continuous glucose monitoring (CGM) data.
Yuan Yao, Zhigang Hu, Yifei Mo, Mingsong Han, Li Cao, Jinghao Cai, Xiaojing Ma, Jingyi Lu, Xiaobing Wu, Jian Zhou   +9 more
wiley   +1 more source

COVID-19 Vaccine-Induced Latent Autoimmune Diabetes in Adults. [PDF]

Cureus, 2023
Bally K, Ji B, Soni L.
europepmc   +1 more source

The Risk of Disease Progression of Type 1 Diabetes in First‐Degree Relatives of People With Type 1 Diabetes: Design and Rationale of a Prospective, Longitudinal Study in China

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4610-4618, June 2026.
ABSTRACT Aims In China, information on individuals who test positive for islet autoantibodies (IAb), including single IAb‐positive individuals and those with early‐stage Type 1 diabetes (T1D), and their risk of progression to Stage 3 T1D is limited. The goal of this study is to assess the risk of progression to T1D in first‐degree relatives (FDRs) of ...
Lixin Guo, Xiaoping Luo, Yan Bi, Bingyan Cao, Guanping Dong, Sheng Jiang, Guijun Qin, Hong Qiao, Zhongyan Shan, Tao Yang, Gaohui Zhu, Min Li, Sunyinyan Tang, Minlu Zhang, Wenjuan Li   +14 more
wiley   +1 more source

Analysis of risk factors and establishment of a prediction model for latent autoimmune diabetes in adults. [PDF]

Ther Adv Endocrinol Metab
Yan H, Lv J, Miao L, Shi L.
europepmc   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Distinct Interplay Between β-Cell Function and Insulin Resistance in Latent Autoimmune Diabetes in Adults Versus Type 2 Diabetes. [PDF]

Diabetes
Amendolara R, De Vita F, Abedi V, Luverà D, Risi R, D'Onofrio L, Zerunian M, Caruso D, Buzzetti R, Maddaloni E.   +9 more
europepmc   +1 more source